Ortin Global Ltd

Stage 4 · Declining · week 1

As of 16 Oct 2026, Ortin Global is in Stage 4 — declining, a downtrend, in its first week (since 15 Oct 2026). It closed at ₹14.34, 28.0% below its 52-week high and below its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. More about the company

₹14.3
+0.28% today
₹12 Cr · Micro cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ORTINGLOBE early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-28.0%
₹11.2 lo₹19.9 hi
28.0% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 1
1w13w26w
Week 1 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-6.4%
200 DMA: ₹15.3 · rising
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.65x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -5.4% vs MA50 -1.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-16.9%
3M
-7.5%
6M
-6.0%
YTD
-0.3%
1Y
+13.9%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2024-08-26 → 2026-10-16
S? 42w
S1 13w
S2 22w
S2 9w
2024-08-262026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S4 1w → S1 13w → S2 2w → S3 1w → S4 7w → S2 22w → S3 4w → S2 9w → S3 8w → S4 1w current
Total tracked: 111 weeks across 11 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-06-12
3 appearances in last 60 days. First seen: 2025-09-29.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S4
Wk 1 · Vol 0.65x
2026-10-15S43→4
Wk 1 · Vol 0.52x
2026-10-14S3
Wk 9 · Vol 1.20x
2026-10-13S3
Wk 8 · Vol 0.76x
2026-10-12S3
Wk 8 · Vol 0.61x
2026-10-09S3
Wk 8 · Vol 0.73x
2026-10-08S3
Wk 8 · Vol 0.92x
2026-10-07S3
Wk 8 · Vol 0.43x
2026-10-06S3
Wk 7 · Vol 0.63x
2026-10-05S3
Wk 7 · Vol 1.79x
2026-10-01S3
Wk 7 · Vol 0.09x
2026-09-30S3
Wk 7 · Vol 0.51x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹15.3
200 DMA
₹15.3
52W High
₹19.9
52W Low
₹11.2
5D Low
₹14.3
Resistance levels (recent highs)
20d High
₹15.8
60d High
₹17.3
120d High
₹19.9
250d High
₹19.9
Next resistance
+10.4%
to 20d High
Ask the Market AI about ORTINGLOBEAsk →
About this companyHealth Care· Pharmaceuticals

Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.